Loading clinical trials...
Loading clinical trials...
The study aims to characterize prospectively longitudinal progression of neurological domains in GM1 and GM2 Gangliosidosis patients with high-quality standards (GCP compliant).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Azafaros A.G.
NCT03333200 · MLD, Krabbe Disease, and more
NCT02254863 · Adrenoleukodystrophy, Batten Disease, and more
NCT06614569 · GM2 Gangliosidosis, Tay Sachs Disease, and more
NCT04713475 · GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, and more
NCT07479953 · GM1 Gangliosidoses, GM1 Gangliosidosis, Type I, and more
UCSF Benioff Children's Hospital
Oakland, California
Mayo Clinic Rochester
Rochester, Minnesota
Hospital Pequeno Principe
Curitiba
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions